Cosciens Biopharma Files 6-K Report

Ticker: CSCIF · Form: 6-K · Filed: Mar 20, 2025 · CIK: 1113423

Sentiment: neutral

Topics: regulatory-filing, corporate-update, pharmaceutical

TL;DR

Cosciens Biopharma (formerly Aeterna Zentaris) filed a routine 6-K update on March 20, 2025.

AI Summary

Cosciens Biopharma Inc. filed a Form 6-K on March 20, 2025, reporting for the month of March 2025. The company, formerly known as Aeterna Zentaris Inc. and Aeterna Laboratories Inc., is a pharmaceutical preparations company. Its principal executive office is located in Toronto, Ontario, Canada.

Why It Matters

This filing provides an update on Cosciens Biopharma's regulatory status and corporate information, which is important for investors tracking the company's ongoing activities.

Risk Assessment

Risk Level: low — This filing is a routine report and does not contain new material financial or operational information that would significantly alter the company's risk profile.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of March 2025.

What are the former names of Cosciens Biopharma Inc.?

Cosciens Biopharma Inc. was formerly known as Aeterna Zentaris Inc. and Aeterna Laboratories Inc.

When was the company's name changed from Aeterna Zentaris Inc.?

The date of the name change from Aeterna Zentaris Inc. is not explicitly stated in this excerpt, but the change from Aeterna Laboratories Inc. was on 20000503.

Where is Cosciens Biopharma Inc.'s principal executive office located?

The principal executive office is located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.

Does Cosciens Biopharma Inc. file annual reports under Form 20-F or Form 40-F?

The registrant indicates it files annual reports under cover of Form 20-F.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on March 20, 2025 regarding COSCIENS Biopharma Inc. (CSCIF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing